Now who’s schizophrenic? Just six months after extending its contract with Otsuka Pharmaceutical to market the Abilify anti-psychotic, the big drugmaker has cut about 25 percent of its Abilify sales team, according to Bloomberg, which notes the pill is the company’s second-biggest seller.

The move happened this week, according to a Bristol-Myers spokesman, who declined to provide specific numbers. “We’re evaluating our resources and determining the most appropriate structure for our sales force,” he told Bloomberg. “It’s an important product for both companies.” Speculation on CafePharma, where reps love to dish the industry dirt, suggests Otsuka will fill the void and may hire some Bristol-Myers reps.

Bristol-Myers sells Abilify in the US and several European countries with Otsuka, which discovered the drug. They agreed in April to extend their contract until April 2015. Abilify faces generic competition in 2012 and, as of last year, is marketed for long-term use by children and teenagers as well as adults.